- ASCO® 2024
- Yale Cancer Answers
- ASH CME Series
- Smilow Shares with Primary Care
- Grand Rounds
- Head and Neck
- Gynecologic
- Benign Hematology
- Breast
- GI
- Lung
- GU
- Hematologic Oncology
- Brain
- Cancer Screening
- DEI (Diversity, Equity and Inclusion)
- 2021 ASH Highlights
- General Events
- Events
Playback speed
10 seconds
Updates on Metastatic Breast Cancer - Yale Cancer Center
By
Yale Cancer Center
FEATURING
Daniel O'Neil
By
Yale Cancer Center
FEATURING
Daniel O'Neil
550 views
November 10, 2023
Disclaimer: "This video was recorded prior to the FDA approval on November 16, 2023, of capivasertib with fulvestrant for HR+/HER2- locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations, as detected by an FDA-approved test, following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy"
Comments 0
Login to view comments.
Click here to Login
Smilow Shares with Primary Care